Israeli acute heart failure (HF) therapy firm Magenta Medical Ltd. has bulked up its coffers with an additional $15m, following a Series B financing that brought in new investors from Japan and the clinical cardiovascular community.
The latest injection of funds is nearly twice the $8.5m raised by the start-up in previous financing rounds, in which Israeli venture capital firm Pitango and Abiomed Inc., developer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?